| Prev Close | 63.84 |
| Open | 64.39 |
| Day Low/High | 63.94 / 64.83 |
| 52 Wk Low/High | 57.19 / 74.12 |
| Volume | 2.93M |
Gilead Sciences, Inc. (GILD)
63.90
0.06
0.09
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 1254.31B |
| Market Cap | 79.36B |
| P/E Ratio | 68.31 |
| Div & Yield | N.A. (N.A) |
Latest News
Gilead Sciences Is Poised for Still Further Gains
We have three new price targets.
Let's Check Up on 2 Immunology-Focused Oncology ETFs
Here we'll look at the iShares Genomics Immunology and Healthcare ETF and the Cancer Immunotherapy ETF to see how they stack up.
3 Big Pharma Buys for Dividend Investors
In a market with elevated valuations and low yields, we see pharmaceutical stocks as a respite from both.
Jim Cramer: Nasdaq's Big Second-Quarter Winners Were Written Off Too Soon
These companies were counted out way too early in the post-pandemic environment and the sellers are experiencing some real regret.
Economics for Dummies, Fed Recap, Fun With Jobs Math, Amazon, Buying ServiceNow
The differences in approach between the two most basic strategies for how to grow an economy are as stark as the division they cause among economists.
Gilead Sciences Quant Upgrade Got Me Thinking
The upgrade got my attention, but positive-looking charts pushed me over the edge.
Turn of the Worm, Treasury Curve, Manchin's Might, Trading Microsoft, Spotify
There is a point where if longer-dated yields move high enough, defensive-minded investors will be drawn from equities to debt securities.
Real Money Post Industrial Average Feels January Chill
The RMPIA easily outpaced the main indexes for 2020, but slipped 1.7% last month.
2 Potential Acquisition Targets as Biotech Deal Activity Picks Up
BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.
Here's What Gilead Sciences Needs to Restart an Uptrend
The shares have been weak since early May.
Eli Lilly: Back From the Depths
I am flat LLY for now. Let's see how the shares behave around the technicals. Then we'll make an equity decision.
What's Going On With the Share Price of Gilead?
The charts tell me there's trouble here.
Election Hopes, Buoyant Banks, Labor Labors Less, FDA's Remdesivir Thumbs Up
Plus, a quick look at Southwest Airlines and why it remains the one airline to own.
A 4.5% Dividend Stock Trading at a Healthy Discount
The stock is simply too cheap, given its strong results to begin 2020, and a highly profitable business model that generates huge amounts of cash flow.
Where Does This Broad Rally Go? Q3 Earnings Begin, Amazon's Prime Day, Apple 5G
What stocks do from here will, beyond electoral risk and potential stimulus, rely upon fourth quarter guidance.
Should You Invest in Regeneron, Lilly, or Gilead?
Invest either because of their profitable portfolio, their impressive pipeline, or their technical set-up.
Trump's Health and the Market, Charts That Matter, Nvidia News, URI Breaks Out
Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.
Real Money Post Industrial Average Outperforms Major Indexes in September
The RMPIA rose 13.8% during the quarter, leaving it up just shy of 29% on a year-to-date basis, thanks to performance by CRM, AAPL , NKE and TMO.
Markets in Limbo, Stimulus Needed, Virus in Charge, Presidential Politics
The short-term story for financial markets has been all about fiscal policy. This remains true.
Jim Cramer: It's Not Just About Stocks, I'm Sticking to What Matters
I don't care for Washington but I have no choice. If I only stick to stocks, I would have buried you.
The Investment Angle of Covid-19
Stocks of companies that have Covid-19 vaccine candidates have boomed while those in the treatment space have not.
2 Dinged Biotech Stocks That Could Reward Investors in the Months Ahead
Shares of Heron Therapeutics and Myovant Sciences have taken hits but both companies still show promise.
Biotech M&A Picks Up: Lessons for Investors and Potential Targets
The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.
Is It Safe Now? Wall Street Bets on Science, Joy in Metville, Citi's Selloff
Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.
The Best Way to Navigate This Market
As is so often the case, the bears are unable to close the deal when it looks like they have an edge.
Jim Cramer: Is This Market Undervalued?
Stocks are reasonable. Or even cheap. There will be more sell-offs ahead but remember this day and do not get too negative.
How About That Merck and Seattle Genetics Deal?
I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.
